Social media

Latest issue out now. Keep up to date on the latest changes in the world of pharma, biotech and medical device clinical trial regulation with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribers who...

New research shows that clinical trials with digital endpoints can be completed 3 to 5 months faster than those without. This can be a difference worth millions. But the benefits of leveraging digital don’t end there. R...

ICON brings a comprehensive approach to obesity asset development, from imaging and diagnostics to adjudication strategies, device experience, and vendor solutions. Visit us at Obesity Week, Nov 4-7 at booth 520 to explo...

ICON leverages real-world evidence to uncover prescriber behavior, payer influence, and patient needs by identifying key subpopulations and quantifying therapeutic impact to build stronger value propositions. Arrange a t...

“Off-the-shelf” scalability, decentralised manufacturing, and regulatory harmonisation—ICON’s leaders explore what it takes to build a sustainable CGT ecosystem in APAC in the article. https://ow.ly/uF3950XgMK6

A successful JCA submission starts with the right evidence. Learn how to align your clinical data with the PICO framework and meet the expectations of EU regulators. Read our whitepaper for actionable guidance: https://...

A successful JCA submission starts with the right evidence. Learn how to align your clinical data with the PICO framework and meet the expectations of EU regulators. Read our whitepaper for actionable guidance: https:/...

ICON’s new whitepaper reveals how smarter monitoring models and evolving CRA roles are reducing trial delays, improving site performance and enabling real-time oversight. Download now: https://www.iconplc.com/insights/t...

ICON’s new whitepaper reveals how smarter monitoring models and evolving CRA roles are reducing trial delays, improving site performance and enabling real-time oversight. Download now: https://lnkd.in/eJcZvnkV

ICH GCP E6(R3) brings major updates to clinical trial standards. From tech integration to participant protection, the changes are wide-ranging. Our PharmaTimes article shows how a strong impact assessment can guide your ...

From risk-based quality management to tech integration - ICH GCP E6(R3) changes everything. Our article in PharmaTimes outlines how a robust impact assessment sets the foundation for successful implementation. Start smar...

Early phase trials in neurodegenerative diseases demand thoughtful design, patient-centricity, and smart biomarker strategies. Join our webinar hosted by ASCPT for a focused discussion on: - Defining target populations a...